Active Recombinant Human Insulin-like Growth Factor Binding Protein 3

• Cat.No.: IGFBP3-145H
• Product Overview: Recombinant Human Insulin-like Growth Factor Binding Protein 3 DNA sequence encoding the human Insulin-like Growth Factor Binding Protein 3 sequence (containing the signal peptide sequence, and the mature human IGFBP-3 sequence) was expressed in modifiedhuman 293 cells.

Specification

• Cat. No.: IGFBP3-145H
• Description: Insulin-like Growth Factor Binding Protein 3 is a member of the insulin-like growth factor binding protein (IGFBP) family. This family includes IGFBP-1 to IGFBP-6 that bind to the insulin-like growth factors (IGFs), thus regulating the half-life, activity, transport, and tissue distribution of the IGFs. Structurally, the IGFBP family of proteins is defined by highly homologous amino and carboxy terminal domains with a structurally diverse central region.
• Source: Human 293 cells.
• Amino Acid Sequence: GASSGGLGPVVRCEPCDARALAQCA PPPAVCAELVREPGCGCCLTCALSE GQPCGIYTERCGSGLRCQPSPDEAR PLQALLDGRGLCVNASAVSRLRAYL LPAPPAPGNASESEEDRSAGSVESP SVSSTHRVSDPKFHPLHSKIIIIKK GHAKDSQRYKVDYESQSTDTQNFSS ESKRETEYGPCRREMEDTLNHLKFL NVLSPRGVHIPNCDKKGFYKKKQCR PSKGRKRGFCWCVDKYGQPLPGYTT KGKEDVHCYSMQSK.
• Molecular Mass: Insulin-like Growth Factor Binding Protein 3 migrates as a broad band between 40 and 45 kDa in SDS-PAGE due to post-translation modifications, in particular glycosylation. This compares with the unmodified IGFBP-3 that has a predicted molecular mass of 28.7 kDa.
• pI: Insulin-like Growth Factor Binding Protein 3 separates into a number of isoforms with a pI between 6.8 and 8.2 in 2D PAGE due to post-translational modifications, in particular glycosylation. This compares with the unmodified IGFBP-3 that has a predicted pI of 8.76.
• % Carbohydrate: Purified Insulin-like Growth Factor Binding Protein 3 consists of 25-35% carbohydrate by weight.
• Purity: >95%, as determined by SDS-PAGE and visualized by silver stain.
• Formulation: When reconstituted in 0.5 ml sterile phosphate-buffered saline, the solution will contain 1% human serum albumin (HSA) and 10% trehalose.
• Reconstitution: It is recommended that 0.5 ml of sterile phosphate-buffered saline be added to the vial.
• Storage: Lyophilized products should be stored at 2 to 8°C. Following reconstitution short-term storage at 4°C is recommended, and longer-term storage of aliquots at -18 to -20°C. Repeated freeze thawing is not recommended.
• Activity: The ED50 of Insulin-like Growth Factor Binding Protein 3 is typically 0.13-0.20 μg/ml as measured by its ability to neutralize rhIGF-II mediated proliferation of the MCF-7 adenocarcinoma cell line.

Gene Information

• Gene Name: IGFBP3 insulin-like growth factor binding protein 3 [ Homo sapiens ]
• Synonyms: IGFBP3; insulin-like growth factor binding protein 3; IBP3; BP-53; binding protein 29; IGF-binding protein 3; growth hormone- dependent binding protein; acid stable subunit of the 140 K IGF complex
• Gene ID: 3486
• mRNA Refseq: NM_000598
• Protein Refseq: NP_000589
• UniProt ID: P17936
• Chromosome Location: 7p13-p12
• MIM: 146732
• Pathway: p53 signaling pathway; Diabetes pathways
• Function: insulin-like growth factor I binding; metal ion binding; protein tyrosine phosphatase activator activity

Reviews

05/04/2020

A manufacturer that offers customization options can enable the researcher to adhere to their experimental design requirements more effectively.

01/20/2019

A reliable manufacturer should be able to provide a consistently pure and high-quality IGFBP3 protein, ensuring that the samples are suitable for research purposes.

01/02/2019

This can help ensure compatibility between different components used in the trials and ease the overall experimental workflow.

Q&As

Are there any genetic factors that influence IGFBP3 protein levels?

Yes, genetic variations can affect IGFBP3 expression, potentially leading to differences in protein levels among individuals.

How does IGFBP3 protein influence bone health?

IGFBP3 is involved in bone metabolism and is associated with bone mineral density. Low levels of IGFBP3 have been linked to decreased bone density and increased risk of fractures.

Are there any side effects associated with therapies targeting IGFBP3?

The potential side effects of therapies targeting IGFBP3 are still being studied, and it varies depending on the specific treatment approach being used.

How do lifestyle factors such as diet and exercise influence IGFBP3 levels?

Healthy lifestyle choices, including a balanced diet and regular exercise, can positively influence IGFBP3 levels, promoting overall health and reducing the risk of related diseases.

What are the implications of IGFBP3 deficiency in children's growth and development?

IGFBP3 deficiency can impact children's growth and development, potentially leading to short stature and delayed puberty, as IGFBP3 is a key regulator of growth hormone actions.